ASP Isotopes (ASPI) shares witnessed positive momentum following significant milestones in its commercial uranium enrichment initiatives across South Africa and the United States. The company's partner, Quantum Leap Energy (QLE), secured a contract with South Africa's Necsa to develop an enrichment facility at the Pelindaba complex. Additionally, ASPI signed a memorandum of understanding with a major U.S. utility to establish domestic production of HALEU and LEU+ nuclear fuels. These developments come as the industry prepares for the 2028 ban on Russian uranium imports, creating an urgent need for alternative supply chains. Canaccord Genuity reaffirmed its 'Buy' rating on ASPI with an $11 price target, highlighting the material transition toward commercial-scale operations. This progress positions the company as a key player in the global shift toward energy security and advanced nuclear technology.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis